STAT+: Who will get the first psychedelic approved?

Gilead’s HIV prevention shot goes generic, Bright Minds’ seizure drug on hold, and more biotech news Adobe Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. The midterms are here. My colleagues will be closely tracking the elections and their implications on health policy, so check back in for our coverage. We also have a helpful primer here. The need-to-know this morning Pfizer earnings. Madrigal Pharma earnings. Alkermes earnings. BioNTech earnings. Vertex Pharma reported earnings on Monday night, as did Neurocrine Biosciences. Who will get the first psychedelic approved? The biotech Compass Pathways has been seen as one of the frontrunners in the race to get the first psychedelic drug approved. But it could be a tight race, with a non-profit organization closing in on its own efforts. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.